Building better models to define therapeutic windows

Selectivity is one of the main challenges faced by researchers, often making it difficult to balance potency and pharmacokinetics while avoiding severe toxicity. It is now understood that drug safety is difficult to achieve by solely taking into account affinity. The evaluation of residence time data for a drug complexed to the primary and collateral targets provides a better understanding of the in vivo drug behavior…